Danish company’s Kalundborg headquarters that manufactures insulin API will be expanded by 2022
Insulin production at Kalundborg site in Denmark
Novo Nordisk has announced plans to invest DKK 800 million ($117m) in upgrading and expanding facilities at its production site in Kalundborg, Denmark. The facility has also been a significant contributor to the company’s environmental agenda.
The facilities currently manufactures a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products.
The projects are expected to be completed in 2022.
“This investment in our production facilities highlights our ambition to continue strengthening our presence in Denmark and Kalundborg. Today, we manufacture around half of the world’s insulin in Kalundborg where we have been present for 50 years,” said Michael Hallgren, Senior VP for Novo Nordisk production in Kalundborg.
Hallgren explained that since the turn of the millennium, Nordisk has invested more than DKK 16 billion ($2.3bn) in these facilities. Nordisk also recently released its financial report for 2019. The report stated that capital expenditure for property, plant and equipment in 2019 was DKK 8.9 billion ($1.3bn) compared with DKK 9.6 billion ($1.4bn) in 2018.
The report also stated: “In 2019, total emissions across operations and transportation was 306,000 tonnes CO2. Emissions are expected to decrease significantly in 2020 due to various renewable energy projects, including solar power across all US operations, wind power in Europe and green steam in Denmark.
Compared to 2018, waste decreased by 13% in 2019. This was due to a decreased amount of both ethanol waste and organic residues from the production of API in Kalundborg.